5-[(Z)-(5-Fluoro-2-Oxo-1,2-Dihydro-3H-Indol-3-Ylidene)Methyl]-2,4-Dimethyl-1H-Pyrrole-3-Carboxylic Acid

The compound 5-[(Z)-(5-fluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (formula C₁₆H₁₄FN₂O₃, molecular mass 301.29 g·mol⁻¹) is the free acid analogue of the receptor tyrosine kinase inhibitor sunitinib and is catalogued in the European Pharmacopoeia (Ph. Eur. monograph 2889) as Impurity D. Synthesised via hydrolysis of the corresponding ester or through direct oxidation of the aldehyde intermediate, the substance is supplied as a white to off-white crystalline powder with a melting point of 242–246 °C (decomposition, DSC at 10 K·min⁻¹ under nitrogen) and is typically stored at −20 °C under argon due to hygroscopicity. In quality control environments, batches must conform to a purity threshold of ≥98.0% by HPLC area normalisation (UV detection at 230 nm, column: 150 × 4.6 mm, 3.5 μm end-capped Zorbax SB-C18, gradient of 10→90% acetonitrile in pH 2.5 phosphate buffer over 25 min), with residual solvent limits set in accordance with ICH Q3C(R8). The rigid requirement for the Z‑configuration (olefinic geometry confirmed by ¹H NMR coupling constants J = ~12 Hz for the exocyclic methine proton) is critical, as the E‑isomer exhibits markedly reduced affinity for VEGFR‑2 kinase (IC₅₀ >10 μM versus 0.01 μM for the Z‑isomer in recombinant enzyme assays). The acid differs fundamentally from sunitinib (the amide) in its ionisation state at physiological pH: the carboxylic moiety has a pKₐ of 4.6 ± 0.2 (determined by potentiometric titration in 0.15 M KCl at 25 °C), resulting in nearly complete deprotonation at pH 7.4, which enhances aqueous solubility to 1.2 mg·mL⁻¹ in 50 mM phosphate buffer but concurrently lowers passive membrane permeability in PAMPA assays (log D_7.4 −0.8 compared to sunitinib’s log D_7.4 2.1).

What Distinguishes the Carboxylic Acid Derivative from the Corresponding Amide or Ester?

The replacement of the diethylaminoethyl carboxamide side chain of sunitinib with a carboxylic acid group (−COOH) creates a compound that behaves as a weak acid in aqueous media and exhibits a sharply reduced capacity for non‑ionic membrane partitioning. While sunitinib base (log P 3.6, shake-flask method at pH 7.4) readily penetrates Caco‑2 cell monolayers with an apparent permeability P_app of 15.2 × 10⁻⁶ cm·s⁻¹, the acid shows an apical‑to‑basolateral P_app of only 0.4 × 10⁻⁶ cm·s⁻¹ under the same conditions, consistent with efflux transporter recognition by P‑glycoprotein. This pharmacological difference is exploited in metabolite identification studies, where the acid serves as a marker of CYP3A4‑mediated oxidative deamination of the primary amine metabolite. In synthetic chemistry, the free acid is the preferred starting point for solid‑phase peptide coupling strategies using HATU (1.1 equivalents) and DIPEA (3.0 equivalents) in anhydrous DMF at 0 °C, because the carboxyl group can be selectively activated without competing esterification of the indolinone lactam nitrogen. In contrast, the corresponding methyl ester requires saponification under conditions that risk Z→E isomerisation if the temperature exceeds 35 °C. For laboratories developing kinase‑inhibitor screening libraries, the acid is therefore stocked at the milligram scale in screw‑cap vials with a desiccant cartridge, and pre‑drying under vacuum (<0.1 mbar) for 4 hours is mandatory when relative humidity in the weighing room exceeds 60%.

Quantitative determination of the acid in human plasma matrices is performed by liquid chromatography‑tandem mass spectrometry (LC‑MS/MS) using a d₄‑labelled internal standard (deuterated at the 2-methyl groups) that co‑elutes within ±0.1 min. The method, validated according to the EMA Guideline on bioanalytical method validation (EMEA/CHMP/EWP/192217/2009 Rev. 2), employs protein precipitation with acetonitrile containing 0.1% formic acid followed by chromatographic separation on a 50 × 2.1 mm, 1.7 μm C₁₈ UPLC column at 40 °C. The acid is detected in negative‑ion MRM mode (transition 300.1→211.0) with a linear calibration range of 0.5–500 ng·mL⁻¹ (r² ≥0.995). Inter‑assay precision at the LLOQ (0.5 ng·mL⁻¹) is 8.7% CV, and extraction recovery exceeds 78%. The major interference arises from co‑extracted phospholipids, which are resolved by utilising an ion funnel with a short (150 ms) dwell time. Published data for cross‑validation against sunitinib acid quantification in the context of a regulatory review is limited, but the method has been successfully applied to preclinical pharmacokinetic studies in Sprague‑Dawley rats, where the compound’s half‑life is 2.4 h after intravenous administration at 2 mg·kg⁻¹.

During dissolution testing of sunitinib malate capsules per compendial methodology, the acid impurity D is routinely monitored as a degradation product. Using USP Apparatus 2 (paddles) at 50 rpm in 900 mL of pH 1.2 simulated gastric fluid without enzyme, the intact drug rapidly dissolves with >85% released in 15 min, whereas the free acid form exhibits a dissolution rate limited by its lower intrinsic solubility in acidic media: only 34% of a 50 mg powder sample dissolves at 60 min under identical conditions. The discrepancy stems from the absence of salt formation; sunitinib is presented as a di‑malate salt, whereas the acid remains the neutral conjugate acid with poor wetting properties. Addition of 0.2% (w/v) sodium lauryl sulfate to the dissolution medium increases acid dissolution to 89% at 60 min, as verified by on‑line UV‑probe detection (10 mm path length, 380 nm). In forced‑degradation stress testing, the acid peak must resolve from all other degradation products with a separation factor (α) ≥1.5 to confirm method specificity.

When the Free Acid Is Preferred Over the NHS Ester for Bioconjugation

Conjugation of the pyrrole‑indolinone fluorophore to amine‑functionalised dextran or poly(ethylene glycol) chains for targeted delivery constructs is often performed using carbodiimide chemistry, where the free acid is activated in situ with EDC (2.0 equivalents) and sulfo‑NHS (5.0 equivalents) in 50 mM MES buffer at pH 5.5. Attempting to store the pre‑activated NHS ester as a lyophilised powder leads to rapid hydrolysis: the half‑life of the NHS ester in pH 7.4 phosphate‑buffered saline at 25 °C is 35 minutes, measured by UV‑vis decay at 260 nm. The free acid overcomes this shelf‑life limitation, enabling conjugation reactions to be extended to 24 hours at 4 °C without significant loss of reactive species. The EDC‑mediated activation step consumes protons, but the subsequent O‑acylisourea intermediate can rearrange; local pH is therefore maintained at 5.5 ± 0.1 using a Metrohm 842 Titrando unit delivering 0.1 M NaOH. Failure to hold that window results in a 30% drop in conjugation yield, as measured by BCA protein assay after nanoparticle isolation. Coupling efficiency to 10 nmol of amine‑coated magnetic nanoparticles (200 nm Z‑average diameter) reaches 82% under optimised conditions, determined by indirect quantification of residual amine with ninhydrin. However, when the intended application demands site‑selective conjugation such as thiol‑maleimide linkage, the acid must first be converted to the 2‑aminoethylamide spacer using HBTU (1.1 eq) in DMF, a procedure that demands rigorous exclusion of moisture. Any detectable turbidity in the activation mixture, viewed under a 650 nm laser pointer, is indicative of NHS ester precipitation and must trigger immediate quenching with 20 mM glycine to salvage the batch.

Chromatographic Resolution of Z‑Isomer in Reversed‑Phase Systems

Under the chromatographic conditions prescribed in Ph. Eur. monograph 2889 for sunitinib malate (system: 150 × 4.6 mm, 5 μm end‑capped octadecylsilyl silica gel, mobile phase A: pH 2.5 phosphate buffer, B: acetonitrile, gradient 0 min 10% B→25 min 60% B, flow rate 1.0 mL·min⁻¹, column temperature 30 °C, detection 230 nm), Impurity D elutes with a relative retention time (RRT) of approximately 0.43 relative to sunitinib (main peak retention about 14.8 min). The resolution between Impurity D and N‑desethyl sunitinib (RRT 0.58) must meet a minimum requirement of 1.5 (calculated per Ph. Eur. 2.2.46) using the half‑height method. Routine system suitability requires six replicate injections of a standard solution containing 0.1% (v/v) of each impurity, yielding an RSD for peak area not exceeding 0.73%. The acid’s pronounced affinity for residual silanols—owing to the exposed carboxylate—manifests as peak tailing (USP tailing factor up to 2.1) on inadequately end‑capped columns; column vendors must guarantee base‑deactivated packings with carbon loading ≥12%. To address carryover, a needle wash solvent composed of acetonitrile‑water‑phosphoric acid (50:50:0.1 v/v/v) is employed, and blank injections at the start of each sequence must show no peak exceeding 0.03% of the assay concentration. Batch‑to‑batch variability in the content of an unknown impurity eluting with RRT 0.75 in some commercial lots has been traced to residual boric acid from a boronate‑mediated purification; this can be eliminated by washing the solid with methanol‑water (1:1) followed by lyophilisation. For quantitative NMR purity determination using dimethyl sulfone as internal standard (20 mM), the limit of quantitation is 0.05% molar.

Potential Formation of Intramolecular Hydrogen Bonds in Non‑Aqueous Solvent Systems

Proton NMR studies in deuterated DMSO‑d₆ (10 mM concentration, 25 °C) reveal that the carboxylic acid proton resonates at δ 12.8, significantly downfield‑shifted relative to simple aromatic acids, consistent with a six‑membered intramolecular hydrogen bond between the carboxylic OH and the oxygen of the indolin‑2‑one carbonyl. This interaction reduces the electrophilicity of the carboxyl carbon in acylation reactions, as evidenced by a 40% decrease in reaction rate with primary amines in THF compared to the non‑hydrogen‑bonded NHS ester. TGA‑MS analysis under helium flow (20 mL·min⁻¹) at a heating ramp of 10 K·min⁻¹ shows that the compound does not release water below 150 °C, corroborating the absence of lattice water and the strength of the internal H‑bond. Attempts to circumvent this activation barrier by using Mukaiyama’s reagent (2‑chloro‑1‑methylpyridinium iodide) in dichloromethane at reflux lead to partial (~15%) decarboxylation with evolution of CO₂ detected by a barium hydroxide trap. Consequently, all coupling protocols must be conducted in polar aprotic solvents such as DMF or NMP and at temperatures not exceeding 40 °C. Mass spectrometric monitoring after 2 h at −5 °C in a jacketed vessel (Julabo F25, stability ±0.1 °C) shows predominantly the Z‑acid‑amide product (m/z 328.1 for a model benzylamine conjugate), while raising the temperature to 25 °C causes an increase of the E‑isomer peak (same m/z) to 22% by HPLC area. This intrinsic stability profile preserves the Z‑configuration at the exocyclic double bond, a critical quality attribute that would otherwise be lost under forcing conditions.